These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27416021

  • 1. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
    Coelho AC, Trinconi CT, Costa CH, Uliana SR.
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
    [No Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
    Coelho AC, Trinconi CT, Costa CH, Uliana SR.
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
    [Abstract] [Full Text] [Related]

  • 3. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL, Engel J.
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [Abstract] [Full Text] [Related]

  • 4. Photodynamic therapy offers a novel approach to managing miltefosine-resistant cutaneous leishmaniasis.
    Cabral FV, Riahi M, Persheyev S, Lian C, Cortez M, Samuel IDW, Ribeiro MS.
    Biomed Pharmacother; 2024 Aug; 177():116881. PubMed ID: 38917757
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
    Emiliano YSS, Almeida-Amaral EE.
    J Nat Prod; 2018 Aug 24; 81(8):1910-1913. PubMed ID: 30095915
    [Abstract] [Full Text] [Related]

  • 6. [Refractory cutaneous leishmaniasis: Benefit of miltefosine].
    Guerveno C, Delavigne K, Berry A, Martin-Blondel G, Delobel P.
    Med Mal Infect; 2019 Jun 24; 49(4):281-283. PubMed ID: 30554949
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL, Simas-Rodrigues C, Silva R, Ürmenyi TP, de Souza W, Rodrigues JC.
    Int J Antimicrob Agents; 2012 Apr 24; 39(4):326-31. PubMed ID: 22226653
    [Abstract] [Full Text] [Related]

  • 8. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
    Dorlo TP, van Thiel PP, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, de Vries PJ.
    PLoS Negl Trop Dis; 2011 Dec 24; 5(12):e1436. PubMed ID: 22180803
    [Abstract] [Full Text] [Related]

  • 9. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
    García Bustos MF, Barrio A, Prieto GG, de Raspi EM, Cimino RO, Cardozo RM, Parada LA, Yeo M, Soto J, Uncos DA, Parodi C, Basombrío MA.
    J Parasitol; 2014 Dec 24; 100(6):840-7. PubMed ID: 25014108
    [Abstract] [Full Text] [Related]

  • 10. Comparison of in vitro Resistance of Wild Leishmania İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis.
    Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M.
    Turkiye Parazitol Derg; 2020 Mar 20; 44(1):12-16. PubMed ID: 32212583
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y.
    Am J Trop Med Hyg; 2006 Dec 20; 75(6):1074-7. PubMed ID: 17172368
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Miltefosine for new world cutaneous leishmaniasis.
    Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H.
    Clin Infect Dis; 2004 May 01; 38(9):1266-72. PubMed ID: 15127339
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
    Killingley B, Lamb LE, Davidson RN.
    Ann Trop Med Parasitol; 2009 Mar 01; 103(2):171-5. PubMed ID: 19208301
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
    Castro MDM, Cossio A, Velasco C, Osorio L.
    PLoS Negl Trop Dis; 2017 Apr 01; 11(4):e0005515. PubMed ID: 28379954
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral miltefosine to treat new world cutaneous leishmaniasis.
    Soto J, Toledo JT.
    Lancet Infect Dis; 2007 Jan 01; 7(1):7. PubMed ID: 17182338
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.